SCHEMBL24252635

SCHEMBL24252635

COc1ccc(B(O)O)cc1-c1ccc2c(N)ccnc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 2/20 0.43
NR4A2 P43354 2/20 0.40
SOS2 Q07890 1/20 0.40
PLG P00747 1/20 0.38
F12 P00748 1/20 0.38
F11 P03951 1/20 0.38
KLKB1 P03952 1/20 0.38
PRSS1 P07477 1/20 0.38
PRSS2 P07478 1/20 0.38
PRSS3 P35030 1/20 0.38
TGFBR1 P36897 1/20 0.38
TLR8 Q9NR97 2/20 0.38
KDR P35968 3/20 0.37
EHMT2 Q96KQ7 1/20 0.37
EHMT1 Q9H9B1 1/20 0.37
MAP4K4 O95819 1/20 0.37
SYK P43405 2/20 0.35
LRRK2 Q5S007 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL25259305 0.94 DHFR (0.39) DHFRNR4A2SOS2PLGF12
Formic Acid SCHEMBL30451532 0.94 DHFR (0.39) DHFRNR4A2SOS2PLGF12
SCHEMBL26771264 0.92 DHFR (0.42) DHFRNR4A2SOS2TGFBR1TLR8
SCHEMBL24252651 0.91 MAP4K4 (0.44) DHFRNR4A2PLGF12F11
SCHEMBL25259303 0.86 DHFR (0.38) DHFRNR4A2SOS2PLGTGFBR1
Formic Acid SCHEMBL30452095 0.85 MAP4K4 (0.41) DHFRNR4A2PLGKDREHMT2
Formic Acid SCHEMBL25257487 0.85 MAP4K4 (0.41) DHFRNR4A2PLGKDREHMT2
SCHEMBL30467809 0.82 PDE10A (0.46) DHFRLRRK2
SCHEMBL24252260 0.82 PDE10A (0.46) DHFRLRRK2
SCHEMBL26771324 0.82 MAP4K4 (0.44) DHFRNR4A2KDREHMT2EHMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 DHFR 1380/4885NR4A2 3794/4885SOS2 4637/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 DHFR 1380/4885NR4A2 3794/4885SOS2 4637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.